IP Library Assignment 068618/0375
Patent Assignment
Reel/Frame 068618/0375

Merger

Recorded: 2024-09-18 Pages: 16
Assignor
SUMITOMO PHARMA ONCOLOGY, INC.
Executed: 2023-09-15
Assignee
SUMITOMO PHARMA AMERICA, INC.
84 WATERFORD DRIVE, MARLBOROUGH, MASSACHUSETTS, 01752
Covered Properties (16)
Imidazo[1,2-Beta]Pyridazine and Pyrazolo[1,5-Alpha]Pyrimidine Derivatives and Their Use as Protein Kinase Inhibitors
Patent: 7,750,007 →
Application: 11/935,959 →
Publication: US 2008/0261988
Methods and Compounds for Treating Pim-1 Kinase-Expressing Cancer Cells
Application: 12/785,322 →
Publication: US 2010/0227861
Imidazo[1,2-B]Pyridazine and Pyrazolo[1,5-a]Pyrimidine Derivatives and Their Use as Protein Kinase Inhibitors
Patent: 8,710,057 →
Application: 13/188,195 →
Publication: US 2011/0281863
SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES AS PROTEIN KINASE INHIBITORS
Patent: 9,416,132 →
Application: 14/234,109 →
Publication: US 2014/0329807
Substituted Imidazo[1,2-B]Pyridazines as Protein Kinase Inhibitors
Application: 15/207,224 →
Publication: US 2017/0002014
Substituted Imidazo[1,2-B]Pyridazines as Protein Kinase Inhibitors
Application: 16/033,038 →
Publication: US 2019/0071446
Substituted Imidazo[1,2-B]Pyridazines as Protein Kinase Inhibitors
Application: 16/460,755 →
Publication: US 2020/0102313
Formulations Comprising Heterocyclic Protein Kinase Inhibitors
Application: 16/789,342 →
Publication: US 2020/0338076
Pim Kinase Inhibitors for Treatment of Myeloproliferative Neoplasms and Fibrosis Associated with Cancer
Application: 17/047,383 →
Publication: US 2021/0113562
Substituted Imidazo[1,2-B]Pyridazines as Protein Kinase Inhibitors
Application: 17/090,857 →
Publication: US 2021/0238183
Formulations Comprising Heterocyclic Protein Kinase Inhibitors
Application: 17/930,015 →
Publication: US 2023/0233557
Substituted Imidazo[1,2-B]Pyridazines as Protein Kinase Inhibitors
Application: 18/424,666 →
Pim Kinase Inhibitors for Treatment of Myeloproliferative Neoplasms and Fibrosis Associated with Cancer
Application: 18/427,222 →
Substituted Imidazo[1,2-B]Pyridazines as Protein Kinase Inhibitors
Application: 18/468,374 →
Substituted Imidazo[1,2-B]Pyridazines as Protein Kinase Inhibitors
Application: 18/741,526 →
Pim Kinase Inhibitors for Treatment of Myeloproliferative Neoplasms and Fibrosis Associated with Cancer
Application: 18/743,075 →
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Mar 28, 2008
From: BEARSS, DAVID J.; LIU, XIAO-HUI; VANKAYALAPATI, HARIPRASAD; XU, YONG
To: SUPERGEN, INC.
Reel/Frame 020721/0348 →
Merger/Name Change Feb 22, 2012
From: SUPERGEN, INC.
To: ASTEX PHARMACEUTICALS. INC.
Reel/Frame 027747/0334 →
Assignment of Assignor's Interest Jul 26, 2012
From: ASTEX PHARMACEUTICALS, INC.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 028650/0717 →
Assignment of Assignor's Interest Aug 12, 2014
From: XU, YONG; BRENNING, BENJAMIN GARY; KULTGEN, STEVEN G.; LIU, XIAOHUI
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 033521/0153 →
Security Interest Nov 17, 2016
From: TOLERO PHARMACEUTICALS, INC.
To: SUMITOMO DAINIPPON PHARMA CO., LTD.
Reel/Frame 040362/0884 →
Assignment of Assignor's Interest Mar 6, 2020
From: WARNER, STEVEN L.; SIDDIQUI-JAIN, ADAM; FLYNN, PAUL
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 052035/0192 →
Assignment of Assignor's Interest Apr 27, 2020
From: XU, YONG; BRENNING, BENJAMIN GARY; KULTGEN, STEVEN G.; LIU, XIAOHUI
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 052500/0211 →
Merger Jul 10, 2020
From: TOLERO PHARMACEUTICALS, INC.
To: BOSTON BIOMEDICAL, INC.
Reel/Frame 053172/0940 →
Change of Name Jul 10, 2020
From: BOSTON BIOMEDICAL, INC.
To: SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.
Reel/Frame 053184/0718 →
Assignment of Assignor's Interest Jul 10, 2020
From: BEARSS, DAVID J.; LIU, XIAO-HUI; VANKAYALAPATI, HARIPRASAD; XU, YONG
To: SUPERGEN, INC.
Reel/Frame 053175/0064 →
Assignment of Assignor's Interest Jul 10, 2020
From: BEARSS, DAVID J.; LIU, XIAO-HUI; VANKAYALAPATI, HARIPRASAD; XU, YONG
To: SUPERGEN, INC.
Reel/Frame 053174/0964 →
Change of Name Jul 16, 2020
From: BOSTON BIOMEDICAL, INC.
To: SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.
Reel/Frame 053225/0690 →
Merger Jul 16, 2020
From: TOLERO PHARMACEUTICALS, INC.
To: SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.
Reel/Frame 053225/0444 →
Corrective Assignment to Correct the Receiving Party Name Previously Recorded on Reel 053225 Frame 0444. Assignor(S) Hereby Confirms the Merger. Jul 17, 2020
From: TOLERO PHARMACEUTICALS, INC.
To: BOSTON BIOMEDICAL, INC.
Reel/Frame 053242/0090 →
Assignment of Assignor's Interest Apr 28, 2021
From: XU, YONG; BRENNING, BEJAMIN GARY; KULTGEN, STEVEN G.; LIU, XIAOHUI
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 056077/0341 →
Merger Apr 28, 2021
From: TOLERO PHARMACEUTICALS, INC.
To: BOSTON BIOMEDICAL, INC.
Reel/Frame 056065/0763 →
Change of Name Apr 28, 2021
From: BOSTON BIOMEDICAL, INC.
To: SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.
Reel/Frame 056077/0354 →
Change of Name Apr 25, 2022
From: SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.
To: SUMITOMO PHARMA ONCOLOGY, INC.
Reel/Frame 059787/0758 →
Change of Name Sep 9, 2022
From: SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.
To: SUMITOMO PHARMA ONCOLOGY, INC.
Reel/Frame 061405/0353 →
Change of Name Sep 9, 2022
From: BOSTON BIOMEDICAL, INC.
To: SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.
Reel/Frame 061405/0345 →
Merger Sep 9, 2022
From: TOLERO PHARMACEUTICALS, INC.
To: BOSTON BIOMEDICAL, INC.
Reel/Frame 061042/0688 →
Assignment of Assignor's Interest Sep 9, 2022
From: WARNER, STEVEN L.; SIDDIQUI-JAIN, ADAM; FLYNN, PAUL
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 061042/0574 →
Change of Name Oct 1, 2024
From: SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.
To: SUMITOMO PHARMA ONCOLOGY, INC.
Reel/Frame 069095/0329 →
Change of Name Oct 1, 2024
From: SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.
To: SUMITOMO PHARMA ONCOLOGY, INC.
Reel/Frame 069094/0505 →
Change of Name Oct 1, 2024
From: BOSTON BIOMEDICAL, INC.
To: SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.
Reel/Frame 069094/0417 →